Patents by Inventor Ronald DeMattos

Ronald DeMattos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Assay method for Alzheimer's disease
    Patent number: 9453069
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: September 27, 2016
    Assignees: ELI LILLY AND COMPANY, WASHINGTON UNIVERSITY
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Humanized antibodies that sequester amyloid beta peptide
    Patent number: 8591894
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: November 26, 2013
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Assay Method for Alzheimer's Disease
    Publication number: 20130230513
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 5, 2013
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Assay method for Alzheimer's disease
    Patent number: 8444977
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: May 21, 2013
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE
    Publication number: 20110158986
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: December 22, 2010
    Publication date: June 30, 2011
    Applicants: ELI LILLY CORPORATION, WASHINGTON UNIVERSITY
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies that sequester amyloid beta peptide
    Patent number: 7892545
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: February 22, 2011
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • ASSAY METHOD FOR ALZHEIMER'S DISEASE
    Publication number: 20100279433
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Assay method for alzheimer's disease
    Patent number: 7771722
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 10, 2010
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE
    Publication number: 20090238821
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: February 8, 2008
    Publication date: September 24, 2009
    Applicant: ELI LILLY CORPORATION
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies that sequester abeta peptide
    Patent number: 7195761
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13–28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: March 27, 2007
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies that sequester abeta peptide
    Publication number: 20060039906
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: September 12, 2005
    Publication date: February 23, 2006
    Inventors: David Holtzman, Ronald DeMattos, Kelly Bales, Steven Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Assay method for alzheimer's disease
    Publication number: 20040248197
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A&bgr;40, A&bgr;42, their ratio, or their rate of entry following administration of antibodies that sequester A&bgr;. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Application
    Filed: February 17, 2004
    Publication date: December 9, 2004
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul, Audrey Yunhua Jia, Naoya Tsurushita, Maximiliano J. Vasquez
  • Humanized antibodies that sequester Abeta peptide
    Publication number: 20040043418
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&bgr; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&bgr;.
    Type: Application
    Filed: August 21, 2002
    Publication date: March 4, 2004
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez